SC grills Sebi over lingering probe against Sandesara brothers despite Rs 5,100 cr settlement
In a surprising turn of events, the Supreme Court has scrutinised Sebi's ongoing actions against the directors of Sterling Biotech. This review arises following the directors’ hefty ₹5,100 crore settlement payment. Earlier, the court had invalidat...
New Delhi: The Supreme Court on Monday questioned the capital markets regulator for not closing proceedings against former directors of Sterling Biotech (SBL), Nitin and Chetan Sandesara, despite its November directions to quash all pending criminal cases after duo paid ₹5,100 crore as part of a mutually agreed one-time settlement.
The top court told the Securities and Exchange Board of India (Sebi) that once the court quashed all cases and payments made by the SBL directors, all proceedings were expected to end.
The bench, comprising Justices JK Maheshwari and Atul S Chandurkar, asked why Sebi was "coming in the way" now despite the court's quashing orders passed November 19.
Also Read: Sebi sets new conditions for intraday borrowing by mutual funds from April 1
The Sandesara brothers' counsel told the court that Sebi had refused to close its probe despite compliance with the apex court order of one-time settlement.
On November 19, the top court had agreed to quash all criminal proceedings against the billionaire Sandesara brothers, subject to them depositing an additional ₹5,100 crore, one-third of the dues they owed in a bank fraud case.
Also Read: Sebi sets up working group to review MF distributor rules, align framework with investment advisers: Tuhin Kanta Pandey
Share in Payments
The court, which said the money deposited be transferred to the banks involved, listed the case for further hearing next Monday.
The Economic Times News App for Quarterly Results, Latest News in ITR, Business, Share Market, Live Sensex News & More.